8-K: Scilex CEO Shifts Focus to Semnur, New $20M PIPE

Scilex Holding Company announces its CEO, Jaisim Shah, will now lead its subsidiary Semnur Pharmaceuticals full-time, alongside a new $20 million private placement for Semnur's SP-102 development, with Henry Ji, Ph.D., appointed as Scilex's new CEO.

Summary

• Jaisim Shah resigned as Chief Executive Officer and President of Scilex Holding Company, effective August 17, 2025, to focus full-time on Semnur Pharmaceuticals, Inc., a majority-owned subsidiary, particularly the development of SP-102.
• Henry Ji, Ph.D., previously Executive Chairperson, was appointed as Scilex's new Chief Executive Officer and President, effective August 17, 2025.
• Semnur Pharmaceuticals, Inc. and Denali Capital Acquisition Corp. entered into a purchase agreement for a $20 million private placement (PIPE Financing).
• The PIPE Financing involves the sale of 1,250,000 shares of common stock of the combined company (New Semnur) at $16.00 per share.
• Proceeds from the PIPE Financing will be used to advance the second Phase 3 clinical trial for SP-102 (SEMDEXA), a non-opioid treatment for lumbosacral radicular pain (LRP)/sciatica.
• The closing of the PIPE Financing is contingent upon the consummation of the business combination between Semnur and Denali, which is expected to close in September 2025.
• Scilex previously engaged in significant related party transactions with its former controlling stockholder, Sorrento Therapeutics, Inc., including a Junior Debtor-in-Possession (DIP) financing of up to $20 million and the repurchase of Sorrento's equity interests in Scilex for an aggregate consideration including $100 million (DIP assumption), a credit bid for the Junior DIP, $10 million cash, and assumption of $12.25 million in legal fees.
• The Stockholder Agreement with Sorrento, which granted Sorrento significant control rights, was terminated on September 21, 2023.

Sentiment

Score: 8

Explanation: The filing indicates a clear strategic direction for Scilex and its key subsidiary Semnur, securing significant funding for a lead product's clinical development and streamlining management focus. The resolution of complex financial ties with Sorrento is also a positive step towards greater independence and clarity.

Positives

• Jaisim Shah's full-time dedication to Semnur is expected to accelerate the development and commercialization of SP-102, a key product candidate.
• The $20 million private placement provides crucial funding for the second Phase 3 clinical trial of SP-102, indicating investor confidence in the product.
• Henry Ji, Ph.D., brings extensive experience in life sciences, corporate leadership, and intellectual property to his new role as Scilex's CEO and President.
• The termination of the Stockholder Agreement with Sorrento removes significant control rights previously held by Sorrento, potentially increasing Scilex's operational autonomy.
• The repurchase of Sorrento's equity interests in Scilex consolidates ownership and resolves complex intercompany financial arrangements stemming from Sorrento's bankruptcy.

Risks

• General economic, political, and business conditions.
• Inability of parties to consummate the private placement.
• Inability of parties to consummate the Business Combination between Semnur and Denali, or occurrence of any event, change, or other circumstances that could give rise to the termination of the merger agreement.
• Outcome of any legal proceedings that may be instituted against the parties following the announcement of the Business Combination.
• Receipt of an unsolicited offer from another party for an alternative business transaction that could interfere with the Business Combination.
• Risk that the approval of Denali's shareholders for the potential transaction is not obtained.
• Failure to realize the anticipated benefits of the Business Combination, including as a result of a delay in consummating the potential transaction or difficulty in integrating the businesses of Semnur or Denali.
• Risk that the Business Combination disrupts current plans and operations as a result of the announcement and consummation of the Business Combination.
• Ability of the combined company to develop and successfully market SP-102 or other products.
• Ability of the combined company to grow and manage growth profitably and retain its key employees.
• Amount of redemption requests made by Denali's shareholders.
• Inability to obtain or maintain the listing or trading of the post-acquisition company's securities on The Nasdaq Stock Market LLC or the over-the-counter markets, as applicable, following the Business Combination.
• Costs related to the Business Combination.

Future Outlook

Semnur Pharmaceuticals, Inc. is expected to become a public company through its business combination with Denali Capital Acquisition Corp., anticipated to close in September 2025. The $20 million private placement will fund the advancement of the second Phase 3 clinical trial for SP-102, aiming for regulatory approval and commercialization for LRP/Sciatica. Jaisim Shah's full-time dedication to Semnur is intended to accelerate SP-102's development, and the combined company (New Semnur) aims to increase access to prescription non-opioid therapeutics.

Management Comments

• "Our team and I are proud to continue our leadership in the creation of prescription non-opioid therapeutics addressing non-opioid pain management for the millions of acute and chronic pain patients." Jaisim Shah, CEO and President of Semnur.
• "Semnur looks to accelerate its mission to increase access to prescription non-opioid therapeutics by further advancing its lead product, SP-102, through the final phase of clinical development for the treatment of LRP/sciatica." Jaisim Shah.
• "We are grateful to all of our investors and partners for supporting us through our successful transition." Jaisim Shah.
• "Jaisim has played a prominent role in Scilex's rapid commercial growth and product development. We credit him with many important strategic contributions, particularly in regards to: Scilex's acquisition of Semnur in 2019; the launch of ZTlido and making ZTlido the number one prescribed branded non-opioid analgesic by pain specialists, with 1 million patients treated since its launch in 2018; in-licensing and launch of ELYXYB and Gloperba; and contributions to the completion of the first SP-102 Phase 3 clinical trial." Henry Ji, Ph.D., Scilex's Chairman and newly appointed CEO and President.
• "We are very appreciative of Jaisim for his work and commitment to Scilex, and we know he will bring tremendous value and leadership skills to Semnur as it is advancing the second Phase 3 clinical trial for the development of SP-102 for the treatment of LRP/sciatica." Henry Ji, Ph.D.

Industry Context

The announcement highlights a strategic focus on non-opioid pain management, aligning with broader healthcare trends emphasizing alternatives to opioids due to the ongoing opioid crisis. The development of SP-102 for lumbosacral radicular pain/sciatica addresses a significant unmet medical need within the chronic pain market. The private placement and business combination for Semnur reflect a trend of specialized pharmaceutical companies seeking capital and public market access to accelerate clinical development for targeted therapies. Scilex's existing commercial products (ZTlido, ELYXYB, Gloperba) position it as a player in the non-opioid pain and related therapeutic areas, with ZTlido noted as a leading prescribed branded non-opioid analgesic by pain specialists.

Management Changes

Corporate Governance

Legal Proceedings

• Sorrento Therapeutics, Inc. and its wholly owned direct subsidiary, Scintilla Pharmaceuticals, Inc. (the Debtors), commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in the Bankruptcy Court.
• The Company provided Junior Debtor-in-Possession (DIP) financing to the Debtors and later repurchased equity interests from Sorrento as part of a resolution within the bankruptcy proceedings.

Related Party Transactions

• Stockholder Agreement with Sorrento: Entered into on September 12, 2022, granting Sorrento significant control rights over Scilex, including director designation and veto power over certain corporate actions. This agreement was terminated on September 21, 2023, following a Bankruptcy Court order.
• Junior Debtor-in-Possession (DIP) Financing with Sorrento: On July 5, 2023, Scilex agreed to provide Sorrento with a non-amortizing super-priority junior secured term loan facility of up to $20 million at 12.00% interest per annum, plus fees. This facility was secured by a second-priority lien on most of Sorrento's assets and granted super priority administrative expense status. It was terminated on September 21, 2023.
• Stock Purchase Agreement with Sorrento (Sorrento SPA): On September 21, 2023, Scilex purchased 1,716,245 shares of Common Stock, 29,057,097 shares of Series A Preferred Stock, and warrants for 128,304 shares of Common Stock from Sorrento. The aggregate consideration included $100 million (assumption of Senior DIP obligations), a credit bid for the Junior DIP Facility, $10 million in cash, and the assumption of approximately $12.25 million in Sorrento's legal fees.
• Credit Bid Pay-Off Letter: On September 21, 2023, in connection with the Sorrento SPA, the Junior DIP Loan Agreement and related documents were terminated and obligations discharged.
• Legal Fee Assumption Letter Agreement: On September 21, 2023, Scilex agreed to assume approximately $12.25 million of Sorrento's legal fees and expenses.

Stakeholder Impact

• Shareholders (Scilex): Potential positive impact from clearer strategic focus, funding for key product development, and resolution of complex related-party transactions with Sorrento, potentially reducing overhang from Sorrento's bankruptcy.
• Shareholders (Semnur/New Semnur): Direct positive impact from the $20 million private placement, providing capital for SP-102 development, and the anticipated public listing via the business combination with Denali.
• Employees (Scilex/Semnur): Management changes clarify leadership roles and strategic priorities, potentially providing stability and focus. Jaisim Shah's dedicated focus on Semnur's SP-102 development could benefit Semnur employees.
• Customers/Patients: Advancement of SP-102 could lead to a new non-opioid treatment option for LRP/Sciatica patients.
• Creditors (Sorrento): The transactions detailed (DIP financing, equity repurchase) are part of the resolution of Sorrento's bankruptcy, impacting its creditors.

Next Steps

• Consummation of the Business Combination between Semnur and Denali Capital Acquisition Corp., expected in September 2025.
• Closing of the $20 million private placement for Semnur, expected immediately following the Business Combination.
• Advancement of the second Phase 3 clinical trial for SP-102 for the treatment of LRP/Sciatica.
• Semnur's continued mission to increase access to prescription non-opioid therapeutics.

Key Dates

Recommendation

The company is making decisive strategic moves by dedicating its former CEO to a high-potential subsidiary (Semnur) and securing significant funding ($20M PIPE) for its lead product candidate (SP-102) which addresses a large unmet medical need in non-opioid pain management. The resolution of the complex financial and governance ties with Sorrento Therapeutics, including the termination of the restrictive Stockholder Agreement and the repurchase of Sorrento's equity, removes a significant overhang and provides greater operational independence. The appointment of Henry Ji, Ph.D., with his extensive industry experience, as the new CEO of Scilex further strengthens leadership. These actions collectively position Scilex and Semnur for accelerated development and potential value creation, making it an attractive investment.

Keywords

Scilex Holding Company, Semnur Pharmaceuticals, Denali Capital Acquisition Corp, SP-102, SEMDEXA, Lumbosacral Radicular Pain, Sciatica, Non-opioid pain management, Private Placement, PIPE Financing, CEO Resignation, CEO Appointment, Henry Ji, Jaisim Shah, Business Combination, Merger Agreement, Sorrento Therapeutics, DIP Financing, Equity Repurchase, Biotechnology, Pharmaceuticals, Clinical Trials, Nasdaq